About 1 million Americans live with ulcerative colitis, a chronic inflammatory disease of the large intestine that almost always starts in the rectum and extends upward in a continuous pattern. Bloody diarrhea is the calling card — and unlike its cousin Crohn’s, UC stays inside the colon and stays inside the inner lining. That sounds like a tidier disease, but tidy doesn’t mean mild. UC patients face the same fatigue, urgency, hospitalizations, and long-term cancer surveillance as anyone with IBD.
The condition typically appears between ages 15 and 30, with a smaller second peak in the 50s and 60s, according to the Crohn’s & Colitis Foundation. This guide covers how UC presents, how doctors confirm it, the modern treatment ladder, and what surgery looks like for the roughly 15 percent of patients who eventually need a colectomy.
What Ulcerative Colitis Is
UC is a relapsing immune-mediated disease confined to the colon. Inflammation always involves the rectum (proctitis) and may extend further: left-sided colitis stops at the splenic flexure, extensive colitis or pancolitis goes beyond it. The inflammation stays superficial — limited to the mucosa and submucosa — which is why fistulas and strictures are rare in UC and common in Crohn’s.
The exact cause remains unknown, but the basic model is well established: a genetically susceptible immune system overreacting to gut bacteria in someone whose colonic mucosal barrier is leakier than normal. Smoking, surprisingly, lowers UC risk and worsens it on cessation, the opposite pattern from Crohn’s disease. UC is one of many immune-mediated illnesses covered in our overview of chronic medical conditions.
Symptoms by Severity
Mild UC means fewer than four stools per day, often with intermittent rectal bleeding and no systemic signs. Moderate UC bumps that to four to six stools daily with more consistent bleeding and crampy abdominal pain. Severe UC — the kind that often lands patients in the hospital — produces more than six bloody stools per day, fever, tachycardia, anemia, and a CRP that climbs into the dozens.
Tenesmus (the urgent feeling of needing to pass stool when the rectum is empty) is highly characteristic. So is nocturnal diarrhea, which sets UC apart from irritable bowel syndrome. Extra-intestinal manifestations occur in 25 to 40 percent of patients: peripheral arthritis, episcleritis, erythema nodosum, primary sclerosing cholangitis. Some manifestations track disease activity; others, like ankylosing spondylitis and PSC, run independent courses.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience more than 10 bloody stools in 24 hours, severe abdominal distension with pain, fever above 101.5 degrees Fahrenheit with rapid heart rate, lightheadedness on standing, or vomiting that prevents fluid intake — these can signal toxic megacolon or acute severe UC requiring inpatient care.
Diagnosis
UC diagnosis combines history, blood work, stool tests, and colonoscopy. Stool studies rule out infectious colitis (C. diff, shigella, campylobacter, E. coli O157, amoeba) and check fecal calprotectin, which is typically several hundred to several thousand mcg/g in active UC. Colonoscopy with biopsies confirms the diagnosis and defines disease extent — a critical determinant of cancer surveillance frequency later.
Histology shows crypt distortion, crypt abscesses, basal plasmacytosis, and goblet cell depletion. The inflammation is continuous from the rectum upward without skip lesions. According to the NIDDK, both endoscopic appearance and biopsy histology should be documented at diagnosis to establish a baseline.
Inducing and Maintaining Remission
Therapy hinges on disease severity and extent. Mild-to-moderate proctitis often responds to topical mesalamine (suppositories or enemas), with oral mesalamine added for left-sided or extensive disease. Total daily oral mesalamine doses of 2.4 to 4.8 grams are standard. About 40 to 50 percent of mild-to-moderate cases reach remission on mesalamine alone within eight weeks.
Moderate-to-severe disease that fails mesalamine moves to oral corticosteroids, then to biologics or small-molecule therapy. Anti-TNF biologics (infliximab, adalimumab, golimumab), vedolizumab, ustekinumab, and JAK inhibitors (tofacitinib, upadacitinib) are all FDA-approved. Sphingosine-1-phosphate modulators (ozanimod, etrasimod) are newer oral options. Per the American College of Gastroenterology guidelines, biologic monotherapy or biologic plus thiopurine combination therapy is preferred for moderate-to-severe disease.
Acute Severe Ulcerative Colitis
About 15 percent of patients experience an episode of acute severe UC, defined by the Truelove and Witts criteria: six or more bloody stools per day plus one of fever, tachycardia, anemia, or elevated ESR. Standard care is hospitalization with IV methylprednisolone 60 mg daily. About 30 to 40 percent fail steroids by day three to five and need rescue therapy with infliximab or cyclosporine — or surgery.
Failure to respond to medical rescue within five to seven days is an indication for urgent colectomy. Delaying surgery in steroid-refractory severe UC raises perforation and mortality risk substantially.
Surgery: Colectomy and J-Pouch
Total proctocolectomy with ileal pouch-anal anastomosis (the J-pouch) is the most common elective surgery in UC. Removing the colon and rectum cures the colonic disease — UC cannot recur in tissue that no longer exists. Most patients do well with the J-pouch, though pouchitis (inflammation of the pouch) affects up to half of patients within five years and is usually treated with antibiotics like ciprofloxacin or metronidazole.
Functional outcomes typically settle to four to eight bowel movements per day with the pouch. About 5 to 10 percent of pouches eventually fail and require conversion to a permanent ileostomy. Quality of life data from large series show comparable scores between J-pouch patients and the general population once they have adapted.
Cancer Surveillance
Long-standing UC raises colorectal cancer risk. Risk climbs after 8 to 10 years of disease, with cumulative incidence around 2 percent at 10 years, 8 percent at 20 years, and 18 percent at 30 years in older studies — newer data with better disease control suggest lower contemporary numbers. The Cleveland Clinic and ACG both recommend surveillance colonoscopy starting eight years after diagnosis (immediately after diagnosis if PSC coexists), repeated every one to three years using high-definition white-light or chromoendoscopy.
When to See a Doctor
Bloody diarrhea is never normal. Even a few episodes warrant evaluation, especially if accompanied by urgency, weight loss, or nighttime symptoms. A primary care physician can run initial labs and stool studies, but a gastroenterologist should perform the diagnostic colonoscopy. Once diagnosed, regular follow-up — typically every three to six months during active disease and every 6 to 12 months in stable remission — keeps treatment optimized.
Frequently Asked Questions
Can ulcerative colitis turn into Crohn’s disease?
UC does not transform into Crohn’s, but about 5 to 10 percent of patients initially diagnosed with UC are reclassified as Crohn’s or indeterminate colitis over time as new findings emerge. Distinguishing the two early matters because surgical options differ — J-pouch is generally avoided in known Crohn’s.
What foods trigger UC flares?
No single food causes UC, and rigid elimination diets rarely change disease course. During flares, many patients tolerate low-residue, lactose-light diets better. The Mediterranean diet has the most evidence for general gut health in IBD, while ultra-processed foods and emulsifiers are increasingly suspected of contributing to inflammation.
Is ulcerative colitis a disability?
UC can qualify as a disability under the ADA when symptoms substantially limit work or daily activities. The Social Security Administration recognizes severe IBD with documented complications under listing 5.06. Many patients work full-time during remission and may need workplace accommodations during flares.
Does ulcerative colitis affect life expectancy?
Modern UC has near-normal life expectancy with appropriate treatment and surveillance. Mortality is slightly elevated only in patients with severe complications, advanced colorectal cancer at diagnosis, or significant comorbid PSC.
The Bottom Line
UC has gone from a disease defined by surgery to one defined by sustained remission on biologic and small-molecule therapy. The diagnostic priority is distinguishing it from infectious colitis and Crohn’s; the therapeutic priority is achieving mucosal healing, not just symptom control. If you are still flaring on mesalamine after three months, ask about escalation. Long-term inflammation drives cancer risk, surgery risk, and disability — and the modern toolkit is broad enough that most patients can find a regimen that works.